Hallucinogen use is associated with a decreased likelihood of positive urine drug screen following entry into community corrections supervision

2017 ◽  
Vol 171 ◽  
pp. e87
Author(s):  
Peter Hendricks ◽  
Sara Lappan ◽  
Karen L. Cropsey
2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Abubakr A. Bajwa ◽  
Scott Silliman ◽  
James D. Cury ◽  
Vandana Seeram ◽  
Adil Shujaat ◽  
...  

To date there is only one single-center study that has exclusively reported characteristics, location, and outcomes of spontaneous intracerebral hemorrhages (ICH) among cocaine users. We aimed to describe the radiological location and characteristics along with clinical outcomes of spontaneous ICH in a similar population. We conducted a retrospective chart review of consecutive patients admitted to a tertiary care hospital, with a spontaneous ICH, who had a urine drug screen performed within 48 hours of admission. Exposure to cocaine was defined by a positive urine drug screen within 48 hours of hospital admission. Demographics, radiographic features of ICH, and short-term clinical outcomes of patients with a positive urine drug screen were analyzed and compared with the cocaine negative group. Among the 102 patients analyzed, 20 (19.6%) had documented exposure to cocaine. There was a predominance of males in both groups with significantly more Blacks in the cocaine positive group (). A statistically significant number of patients with cocaine use had ICH in a subcortical location () when compared to cocaine negative patients. There was no difference in GCS, ICH volume, intraventricular extension, ICU days, hospital days, hospital cost, mortality, and ICH score. ICH in cocaine use is more frequently seen in the subcortical location.


PEDIATRICS ◽  
1993 ◽  
Vol 91 (2) ◽  
pp. 350-354 ◽  
Author(s):  
W. T. Weathers ◽  
K. J. Sauvain ◽  
M. M. Crane ◽  
D. W. Blackhurst

Adverse health effects associated with intrauterine cocaine exposure (prematurity and its associated morbidity, intrauterine growth retardation, possible risk of sudden infant death syndrome) are based on studies from large urban hospitals, but few data exist from other sources. The current study, set in a community hospital, was designed to (1) estimate the prevalence of maternal cocaine use at delivery, (2) describe neonatal outcomes, and (3) evaluate physiological growth in exposed children. The study was conducted over 30 months (total births were 14 074) at The Children's Hospital of Greenville Memorial Hospital, the major source of neonatal care for Greenville County, South Carolina (1990 population: 320 000). A child was considered exposed to cocaine if there was documented evidence of use in the mother's medical record or if one member of the pair had a positive urine drug screen. Growth data were abstracted from clinical records. Overall prevalence of exposure was 1.0%. Of the 137 subjects (89, positive urine drug screen; 48 self-reported exposure), 21 (15%, 95% confidence interval, 9% to 21%) were premature (gestational age <37 weeks) and 2 died of sudden infant death syndrome. Mean age- and sex-adjusted percentiles for weight, length, and head circumference increased from 23%, 29%, and 18%, respectively, at birth to 43%, 49%, and 54% in children followed for 12 months; however, 50% of the cohort were lost to follow-up, and these children were smaller at birth than those under active follow-up. Rates of prematurity and infant death were similar to those reported in urban hospitals. These data support the concept that cocaine-exposed children can achieve expected growth levels by 1 year of age.


2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Sumit Sohal ◽  
Mina Sous ◽  
Gauri Pethe ◽  
Shanmugha V. Padmanabhan ◽  
Rajesh Akbari ◽  
...  

Advanced heart failure patients commonly suffer from ventricular arrhythmias which can be managed by antiarrhythmic drugs like mexiletine. These ventricular arrhythmias can be complicated by illicit drug use which alter outcomes and can potentially impact the patient-physician relationship through countertransference. However, mexiletine can lead to false positive urine drug screen testing for amphetamine, and these false-positive urine drug screen test results can affect the decision-making process. Health care providers should be aware of this fact and should either use confirmatory testing or look for confounding compounds in patients who deny using illicit substances and have a positive urine drug screen. Our patient is 64 years old who arrived at the emergency department after experiencing a shock by his intracardiac defibrillator. The patient tested positive for amphetamine on his urine drug screen and was later ruled out by confirmatory quantitative testing.


2012 ◽  
Vol 50 (10) ◽  
pp. 1174-1175 ◽  
Author(s):  
Schirin Tang ◽  
Michael E. Mullins ◽  
Benjamin M. Braun ◽  
Karl G. Hock ◽  
Mitchell G. Scott ◽  
...  

2006 ◽  
Vol 130 (12) ◽  
pp. 1834-1838
Author(s):  
Stacy E. F. Melanson ◽  
Elizabeth Lee-Lewandrowski ◽  
David A. Griggs ◽  
William H. Long ◽  
James G. Flood

Abstract Context.—Emergency department physicians frequently request urine drug screens, but many are unaware of their limitations, including the potential for false-positive results. Promethazine, a phenothiazine derivative, is used for the treatment of allergies, agitation, nausea, and vomiting. Many patients taking promethazine are subject to urine drug screens and any potential interferences are important to recognize. Design.—During an 11-month period, all patients presenting to the Massachusetts General Hospital emergency department who had a finding of promethazine in their serum drug screen, and who also had a urine drug screen performed, were selected for inclusion in the study. The urine drug screen results (n = 22 patients/samples) were then studied. Objective.—To determine if promethazine use can cause false-positive urine amphetamine results in widely used drug of abuse immunoassays. Results.—Thirty-six percent of patients taking promethazine had false-positive test results for urine amphetamines using the EMIT II Plus Monoclonal Amphetamine/Methamphetamine Immunoassay. Sixty-four percent of patients showed cross-reactivity greater than 20% higher than the blank calibrator rate. In a separate, related study, no promethazine-induced false-positive results were seen with the EMIT II Plus, Triage, and TesTcard 9 amphetamine assays, or the Triage methamphetamine assay. Reduced chlorpromazine interference was also seen with these other assays. Conclusions.—False-positive urine amphetamine results can be obtained in patients taking promethazine. Promethazine metabolite(s), and not the parent compound, are the likely cause of these urine false-positive results obtained with EMIT II Plus Monoclonal Amphetamine/Methamphetamine Immunoassay. Immunoassays from different manufacturers can have very different “interference” profiles, which the pathologist and laboratory scientist must understand and relay to clinicians.


2009 ◽  
Vol 2009 (mar08 1) ◽  
pp. bcr0920080879-bcr0920080879 ◽  
Author(s):  
H. Syed ◽  
S. Som ◽  
N. Khan ◽  
W. Faltas

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Katherine Callaghan ◽  
David I. Rappaport

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Joshua L. Fenderson ◽  
Amy N. Stratton ◽  
Jennifer S. Domingo ◽  
Gerald O. Matthews ◽  
Christopher D. Tan

The aim of this paper is to report the first case of atomoxetine leading to false-positive urine drug screen. An otherwise healthy 27-year-old female with a history of attention deficit hyperactivity disorder (ADHD) treated with atomoxetine had an acute onset tonic-clonic seizure. On arrival to the hospital, a urine toxicological drug screen with immunochemical cloned enzyme donor immunoassay (CEDIA) was performed. Results were positive for amphetamines; however, the presence of these substances could not be confirmed with urine gas chromatography-mass spectrometry (GC-MS). She denied any illicit drug use, herbal medications, or supplements, and her other prescription medications have not been previously known to cause a false-positive result for amphetamines. While stimulant treatments for ADHD could certainly result in a positive result on urine screen for amphetamines, there have been no reports of false-positive results for amphetamines secondary to patients using atomoxetine. We implicate atomoxetine, and/or its metabolites, as a compound or compounds which may interfere with urine drug immunoassays leading to false-positive results for amphetamines CEDIA assays.


Sign in / Sign up

Export Citation Format

Share Document